ICS works by stimulating T cells and adding protein transport inhibitors during stimulation, so cytokines made in response stay inside the cell, where antibodies detect them after fixation and permeabilization. The method, developed in the 1990s, rests on the observation that blocking secretion lets a cytokine accumulate to levels flow cytometry can read in single cells, alongside the markers that say which cells they are.
We stimulate PBMCs with the antigen alongside a DMSO vehicle control and positive controls. For human samples, the positive controls are typically the CEF and CEF/TA peptide pools, which recall responses to common viral and vaccine antigens in CD8+ and CD4+ T cells. An antibody to CD107a is present from the start, so that it labels cells that degranulate during stimulation. Stimulations of 4, 6, and 18 hours are all typical, with the length chosen for the stimulus and the markers a study reads. In a 6-hour stimulation, for example, we add brefeldin A and monensin after the first 2 hours, so the cells spend the remaining 4 hours under the secretion block. Where a study calls for it, we add co-stimulation with antibodies to CD28 and CD49d, which can lower the activation threshold of some memory T cells.
Staining begins with a viability dye, because dead cells can bind antibodies nonspecifically and have been reported to inflate an apparent antigen-specific response. We then block Fc receptors, stain surface markers, and fix the cells before permeabilizing them and staining the intracellular targets. Where the schedule of a run calls for it, we hold the fixed cells at 4°C overnight before permeabilization, a step that serves timing rather than the method itself. We acquire samples by spectral flow cytometry, which records the full emission spectrum of every fluorochrome and separates their signals by unmixing against single-stain reference controls, so one panel can carry the lineage, memory, and functional markers together. We add sample-specific unstained controls to account for each sample’s autofluorescence.
We analyze every sample in a study against one gating hierarchy, agreed with you at scoping: acquisition stability over time, lymphocytes, single cells, viable cells, and CD3+ T cells, then CD4+ and CD8+ T cells, their memory subsets, and each function within each subset. Gating is a recognized source of variability in ICS between laboratories, so applying one hierarchy across arms, timepoints, and sites lets the results be read as one dataset.

